{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T02:23:35Z","timestamp":1790130215484,"version":"4.0.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015322","name":"National Cancer Center Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2021-A-12"],"award-info":[{"award-number":["2021-A-12"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008746","name":"National Cancer Center","doi-asserted-by":"publisher","award":["2024-A-08"],"award-info":[{"award-number":["2024-A-08"]}],"id":[{"id":"10.13039\/100008746","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejca.2025.116034","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:11:54Z","timestamp":1759540314000},"page":"116034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study"],"prefix":"10.1016","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4085-0741","authenticated-orcid":false,"given":"Kazumasa","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5041-2765","authenticated-orcid":false,"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-2895","authenticated-orcid":false,"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Wakabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9763-9366","authenticated-orcid":false,"given":"Eiji","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Saltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis JA","family":"Punt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Koopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-1230","authenticated-orcid":false,"given":"Eric","family":"Van Cutsem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6071-7810","authenticated-orcid":false,"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan P.","family":"Venook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":false,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cremolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Randolph Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-8832","authenticated-orcid":false,"given":"Qian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimery","family":"de Gramont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.116034_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2025.116034_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101558","article-title":"Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with metastatic colorectal cancer","volume":"8","author":"Yoshino","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2025.116034_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1200\/JCO.22.01690","article-title":"Treatment of metastatic colorectal cancer: ASCO guideline: ASCO guideline","volume":"41","author":"Morris","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib5","unstructured":"National Comprehensive Cancer Network; 2025. NCCN clinical practice guidelines in oncology: Colon cancer. version 1.2025, https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"key":"10.1016\/j.ejca.2025.116034_bib6","unstructured":"US Food and Drug Administration, https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm, [accessed February 24, 2025]."},{"key":"10.1016\/j.ejca.2025.116034_bib7","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib8","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdm496","article-title":"KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab","volume":"19","author":"De Roock","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib9","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1200\/JCO.2007.12.5906","article-title":"KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab","volume":"26","author":"Li\u00e8vre","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.116034_bib11","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib12","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial","volume":"17","author":"Stintzing","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib13","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.116034_bib14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2025.116034_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2009.25.2544","article-title":"Toward efficient trials in colorectal cancer: the ARCAD clinical trials program","volume":"28","author":"de Gramont","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116034_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.116034_bib17","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejca.2025.116034_bib18","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2025.116034_bib19","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAF V600E mutation in First-Line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database","volume":"113","author":"Cohen","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.ejca.2025.116034_bib20","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-Mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.ejca.2025.116034_bib21","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-Mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.116034_bib22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41591-024-03443-3","article-title":"Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial","volume":"31","author":"Kopetz","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2025.116034_bib23","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ijc.33200","article-title":"Informing metastatic colorectal cancer patients by quantifying multiple scenarios for survival time based on real-life data","volume":"148","author":"Hamers","year":"2021","journal-title":"Int J Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925006203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:33:17Z","timestamp":1773153197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925006203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":23,"alternative-id":["S0959804925006203"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116034"}}